Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H29N3O.2ClH |
Molecular Weight | 436.418 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OCCN1CCN(CCCN2C3=C(C=CC=C3)C=CC4=C2C=CC=C4)CC1
InChI
InChIKey=DLTOEESOSYKJBK-UHFFFAOYSA-N
InChI=1S/C23H29N3O.2ClH/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26;;/h1-4,6-11,27H,5,12-19H2;2*1H
Molecular Formula | C23H29N3O |
Molecular Weight | 363.4959 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25722522
Sources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25722522
Opipramol (Insidon, Pramolan, Ensidon, Oprimol) is an antidepressant and anxiolytic used in Germany and other European countries. Although it is a member of the tricyclic antidepressants, opipramol's primary mechanism of action is much different in comparison, it doesn’t represent a tricyclic antidepressant drug as it does not inhibit the neuronal uptake of norepinephrine and/or serotonin. Opipramol also acts as a low to moderate affinity antagonist for the D2, 5-HT2, H1, H2, and muscarinic acetylcholine receptors. H1 and H2 receptor antagonism account for its antihistamine effects, and muscarinic acetylcholine receptor antagonism is responsible for its anticholinergic properties. Opipramol was developed by Schindler and Blattner in 1961. Opipramol is typically used in the treatment of generalized anxiety disorder (GAD) and somatoform disorders. Its anxiolysis becomes prominent after only one to two weeks of chronic administration. Upon first commencing treatment, opipramol is rather sedating in nature due to its antihistamine properties, but this effect becomes less prominent with time. The therapy with Opipramol indicates an additional therapy with neuroleptics, hypnotics and tranquilizers (e.g. Barbiturates, Benzodiazepines). Therefore, it should be noted that some specific reactions, particularly CNS depressant effects could be intensified and an intensification of common side effects may occur. If necessary the dosage may be reduced. Co-administration with alcohol can cause stupor. MAO Inhibitors should be discontinued at least 14 days before the treatment with Opipramol. Concomitant use of Opipramol with β-blockers, antiarrhythmics (of class 1c), as well as drugs from tricyclic antidepressant group and preparations which influence the microsomal enzyme system, can lead to change in plasma concentration of these drugs. Co-administration of neuroleptics (example- haloperidol, risperidone) can increase the plasma concentration.
Originator
Sources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdf
Curator's Comment: 1961
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11199949 |
|||
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25722522 |
|||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25722522 |
|||
Target ID: CHEMBL2095200 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25722522 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous determination of seven tricyclic antidepressant drugs in human plasma by direct-injection HPLC-APCI-MS-MS with an ion trap detector. | 2002 Aug |
|
The treatment of generalised anxiety disorder. A systematic review. | 2002 Dec |
|
[Somatoform disorders--what must the general practitioner know?]. | 2004 Aug 19 |
|
Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. | 2005 Oct |
|
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | 2006 Oct 20 |
|
sigma-1 receptor modulation of acid-sensing ion channel a (ASIC1a) and ASIC1a-induced Ca2+ influx in rat cortical neurons. | 2008 Nov |
|
Opipramol dipicrate. | 2010 Jul 10 |
|
In vitro studies of DNA damage caused by tricyclic antidepressants: a role of peroxidase in the side effects of the drugs. | 2010 Sep 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdf
50 mg in morning; 50 mg in the afternoon and 100 mg in the evening
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:10:30 GMT 2023
by
admin
on
Fri Dec 15 15:10:30 GMT 2023
|
Record UNII |
B49OBI656M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5045752
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
C87667
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
71587
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
m8218
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
213-000-2
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
82062
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL370753
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
100000092384
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
909-39-7
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
SUB03520MIG
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
B49OBI656M
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |